Genmab — Februar 2017
-
Dette er sådan set en gammel nyhed, men er vist lidt overset (fra Genmabs hkjemmeside): In May 2014 Genmab entered a research collaboration with Cormorant to evaluate our DuoBody
technology for the creation of a bispecific antibody against IL-8 and an undisclosed target. This agreement was also transferred to BMS as the result of their acquisition of Cormorant.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind